Ballicules.com

Nebivolol

BYSTOLIC

What it isBeta-1 antagonist with beta-3 agonism and nitric-oxide vasodilation; hypertension.

Why this oneIt uniquely couples beta-1 blockade to beta-3-mediated vasodilation, separating it from conventional beta blockers.

What limits itBradycardia still limits use; beta-1 selectivity fades as exposure rises, and CYP2D6 inhibition can markedly raise levels.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
HypertensionAdults5 mg QDindividualized40 mg QD

Titration Increase at 2-week intervals

Renal Severe (CLcr <30 mL/min): start 2.5 mg QD, titrate slowly; not studied in dialysis

Hepatic Moderate impairment: start 2.5 mg QD, titrate slowly; contraindicated/not recommended in severe (Child-Pugh >B)

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Data insufficient; third-trimester beta-blocker risk of neonatal hypotension, bradycardia, hypoglycemia, respiratory depression

Lactation Not recommended during nursing (beta-blocker risk, esp. bradycardia)

NO BOXED WARNINGS

Principal riskBradycardia; the most beta-1 selective

Cost, est. cash$5–$150/month

Generic entry2015

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger3 / 4
Weight-gain liability1 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityBradycardia, hypotension and bronchospasm; overdose may cause conduction block or cardiogenic shock.

Mechanism of action: Nebivolol ballicule

Nebivolol ballicule: receptor binding, kinetics and half-life diagram

Open Nebivolol in the interactive console ↗

Memory aids: mascots and interaction avatars

Nebivolol Bystolic mascot mnemonic cartoon
“Nebula Bystander”
LOL hat → beta blocker
Nebivolol CYP2D6 substrate avatar
CYP2D6 substrate

Open Nebivolol in the interactive console ↗